


**Product Name** : CCS1477  
**Cat. No.** : PC-38126  
**CAS No.** : 2222941-37-7  
**Molecular Formula** : C<sub>31</sub>H<sub>35</sub>F<sub>2</sub>N<sub>3</sub>O<sub>3</sub>  
**Molecular Weight** : 535.636  
**Target** : Histone Acetyltransferase (HAT)  
**Solubility** :



### Biological Activity

CCS1477 (Inobrodib) is an orally bioavailable, potent, and selective inhibitor of the **p300/CBP bromodomain**, binds to p300 and CBP with K<sub>d</sub>s of 1.3 and 1.7 nM respectively.

CCS1477 (Inobrodib) displays > 170/130-fold selectivity compared with BRD4, CCS1477 binding to cellular histones in an in-cell BRET assay, with an IC<sub>50</sub> of 19 nM for p300 and 1060 nM for BRD4.

CCS1477 (Inobrodib) has only minimal binding to BRD2, 3, 4, 9 and WDR9 (14-33% of control at 1 μM) in a bromoscan assay of 32 bromodomains.

CCS1477 inhibits cell proliferation in prostate cancer cell lines and decreases AR- and C-MYC-regulated gene expression.

CCS1477 has antitumor activity, regulating AR and C-MYC signaling in AR-SV-driven models.

CCS1477 modulates KLK3 blood levels and regulates CRPC biopsy biomarker expression.

### References

Jonathan Welti, et al. Cancer Discov. 2021 May;11(5):1118-1137.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com